Ipsen has announced that following shareholder approval of Vernalis, the company has completed its purchase of Apokyn and Vernalis's US commercial operations.
Subscribe to our email newsletter
The subscription by Ipsen for 35.25 million new ordinary shares of GBP0.05 each in the capital of Vernalis, as part of the purchase arrangements, has also been completed.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.